The Production of a Recombinant Tandem Single Chain Fragment Variable Capable of Binding Prolamins Triggering Celiac Disease

Overview

Journal BMC Biotechnol

Publisher Biomed Central

Specialty Biotechnology

Date 2018 May 31

PMID 29843684

Citations 4

Authors

Britta Eggenreich

Elke Scholz

David Johannes Wurm

Florian Forster

Oliver Spadiut

Affiliations

Soon will be listed here.

Abstract

Background: Celiac disease (CD) is one of the most common food-related chronic disorders. It is mediated by the dietary consumption of prolamins, which are storage proteins of different grains. So far, no therapy exists and patients are bound to maintain a lifelong diet to avoid symptoms and long-term complications. To support those patients we developed a tandem single chain Fragment variable (tscFv) acting as a neutralizing agent against prolamins. We recombinantly produced this molecule in E. coli, but mainly obtained misfolded product aggregates, so-called inclusion bodies, independent of the cultivation strategy we applied.

Results: In this study, we introduce this novel tscFv against CD and present our strategy of obtaining active product from inclusion bodies. The refolded tscFv shows binding capabilities towards all tested CD-triggering grains. Compared to a standard polyclonal anti-PT-gliadin-IgY, the tscFv displays a slightly reduced affinity towards digested gliadin, but an additional affinity towards prolamins of barley.

Conclusion: The high binding specificity of tscFv towards prolamin-containing grains makes this novel molecule a valuable candidate to support patients suffering from CD in the future.

Citing Articles

Potential Application of Recombinant Snake Prothrombin Activator Ecarin in Blood Diagnostics.

Zhao K, Masci P, Dimeski G, Johnson L, Grant M, de Jersey J Biomolecules. 2022; 12(11).

PMID: 36421717 PMC: 9687618. DOI: 10.3390/biom12111704.

The mosaic puzzle of the therapeutic monoclonal antibodies and antibody fragments - A modular transition from full-length immunoglobulins to antibody mimetics.

Khatib S, Salla M Leuk Res Rep. 2022; 18:100335.

PMID: 35832747 PMC: 9272380. DOI: 10.1016/j.lrr.2022.100335.

The impact of technical failures during cultivation of an inclusion body process.

Pekarsky A, Konopek V, Spadiut O Bioprocess Biosyst Eng. 2019; 42(10):1611-1624.

PMID: 31267174 PMC: 6751153. DOI: 10.1007/s00449-019-02158-x.

Evolving Therapy for Celiac Disease.

Yoosuf S, Makharia G Front Pediatr. 2019; 7:193.

PMID: 31157194 PMC: 6530343. DOI: 10.3389/fped.2019.00193.

References

Guglielmi L, Martineau P . Expression of single-chain Fv fragments in E. coli cytoplasm. Methods Mol Biol. 2009; 562:215-24. PMC: 3101525. DOI: 10.1007/978-1-60327-302-2_17. View

Matsui T, Sato H, Yamamuro H, Shinzato N, Matsuda H, Misawa S . High cell density cultivation of recombinant E. coli for hirudin variant 1 production by temperature shift controlled by pUC18-based replicative origin. Appl Microbiol Biotechnol. 2008; 80(5):779-83. DOI: 10.1007/s00253-008-1611-2. View

Tack G, Verbeek W, Schreurs M, Mulder C . The spectrum of celiac disease: epidemiology, clinical aspects and treatment. Nat Rev Gastroenterol Hepatol. 2010; 7(4):204-13. DOI: 10.1038/nrgastro.2010.23. View

Eggenreich B, Rajamanickam V, Wurm D, Fricke J, Herwig C, Spadiut O . A combination of HPLC and automated data analysis for monitoring the efficiency of high-pressure homogenization. Microb Cell Fact. 2017; 16(1):134. PMC: 5540504. DOI: 10.1186/s12934-017-0749-y. View

El-Salhy M, Gundersen D, Gilja O, Hatlebakk J, Hausken T . Is irritable bowel syndrome an organic disorder?. World J Gastroenterol. 2014; 20(2):384-400. PMC: 3923014. DOI: 10.3748/wjg.v20.i2.384. View

Green P, Lebwohl B, Greywoode R . Celiac disease. J Allergy Clin Immunol. 2015; 135(5):1099-106. DOI: 10.1016/j.jaci.2015.01.044. View

Hundsberger H, Koppensteiner A, Hofmann E, Ripper D, Pfluger M, Stadlmann V . A Screening Approach for Identifying Gliadin Neutralizing Antibodies on Epithelial Intestinal Caco-2 Cells. SLAS Discov. 2017; 22(8):1035-1043. DOI: 10.1177/2472555217697435. View

Schuppan D, Junker Y, Barisani D . Celiac disease: from pathogenesis to novel therapies. Gastroenterology. 2009; 137(6):1912-33. DOI: 10.1053/j.gastro.2009.09.008. View

Nelson A . Antibody fragments: hope and hype. MAbs. 2010; 2(1):77-83. PMC: 2828581. DOI: 10.4161/mabs.2.1.10786. View

10.

Baeshen N, Baeshen M, Sheikh A, Bora R, Ahmed M, Ramadan H . Cell factories for insulin production. Microb Cell Fact. 2014; 13:141. PMC: 4203937. DOI: 10.1186/s12934-014-0141-0. View

11.

Bu D, Zhou Y, Tang J, Jing F, Zhang W . Expression and purification of a novel therapeutic single-chain variable fragment antibody against BNP from inclusion bodies of Escherichia coli. Protein Expr Purif. 2013; 92(2):203-7. DOI: 10.1016/j.pep.2013.10.002. View

12.

Adams G, Schier R, Marshall K, Wolf E, McCALL A, Marks J . Increased affinity leads to improved selective tumor delivery of single-chain Fv antibodies. Cancer Res. 1998; 58(3):485-90. View

13.

Villaverde A . Bacterial inclusion bodies: an emerging platform for drug delivery and cell therapy. Nanomedicine (Lond). 2012; 7(9):1277-9. DOI: 10.2217/nnm.12.100. View

14.

Bascunan K, Vespa M, Araya M . Celiac disease: understanding the gluten-free diet. Eur J Nutr. 2016; 56(2):449-459. DOI: 10.1007/s00394-016-1238-5. View

15.

Rashtak S, Murray J . Review article: coeliac disease, new approaches to therapy. Aliment Pharmacol Ther. 2012; 35(7):768-81. PMC: 3912561. DOI: 10.1111/j.1365-2036.2012.05013.x. View

16.

Baeshen M, Al-Hejin A, Bora R, Ahmed M, Ramadan H, Saini K . Production of Biopharmaceuticals in E. coli: Current Scenario and Future Perspectives. J Microbiol Biotechnol. 2015; 25(7):953-62. DOI: 10.4014/jmb.1412.12079. View

17.

Comino I, Moreno M, Real A, Rodriguez-Herrera A, Barro F, Sousa C . The gluten-free diet: testing alternative cereals tolerated by celiac patients. Nutrients. 2013; 5(10):4250-68. PMC: 3820072. DOI: 10.3390/nu5104250. View

18.

Villaverde A, Carrio M . Protein aggregation in recombinant bacteria: biological role of inclusion bodies. Biotechnol Lett. 2003; 25(17):1385-95. DOI: 10.1023/a:1025024104862. View

19.

Stadlmann V, Harant H, Korschineck I, Hermann M, Forster F, Missbichler A . Novel avian single-chain fragment variable (scFv) targets dietary gluten and related natural grain prolamins, toxic entities of celiac disease. BMC Biotechnol. 2015; 15:109. PMC: 4666168. DOI: 10.1186/s12896-015-0223-z. View

20.

Sun H, Wu G, Chen Y, Tian Y, Yue Y, Zhang G . Expression, production, and renaturation of a functional single-chain variable antibody fragment (scFv) against human ICAM-1. Braz J Med Biol Res. 2014; 47(7):540-7. PMC: 4123832. DOI: 10.1590/1414-431x20143276. View